Silexion Therapeutics Corp
Business
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company developing proprietary RNA-interference therapeutics to treat KRAS-driven cancers. It primarily advances siRNA candidates, notably second‑generation SIL204 and first‑generation siG12D‑LODER, intended for intratumoral administration in combination with standard‑of‑care chemotherapy to silence KRAS mutations such as G12D and G12V. Key business activities comprise research and development, preclinical and clinical trials, third‑party manufacturing partnerships and regulatory engagement. The company conducts multinational clinical studies and distributes through clinical sites and contract research and manufacturing organizations in the U.S., EU and Israel.
Summary from filing dated 2025-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development (including $0 and $1,796 from related party, for the year ended December 31, 2025 and December 31, 2024, respectively) | 7 | 6 | 4 | |
| General and administrative (including $134 and $2,972 from related party, for the years ended December 31, 2025 and December 31, 2024, respectively) | 4 | 7 | 973,000 | |
| TOTAL OPERATING EXPENSES | 12 | 13 | 5 | |
| OPERATING LOSS | 12 | 13 | 5 | |
| Financial expenses (income), net (including $232 and $(1,249) from related party, for the years ended December 31, 2025 and December 31, 2024, respectively) | 277,000 | 4 | 395,000 | |
| LOSS BEFORE INCOME TAX | 12 | 17 | 5 | |
| INCOME TAX | 3,000 | 10,000 | 32,000 | |
| NET LOSS FOR THE YEAR | 12 | 17 | 5 | |
| Equity holders of the Company | 12 | 16 | 5 | |
| Non-controlling interests | 0 | 76,000 | 166,000 | |
| LOSS PER ORDINARY SHARE, BASIC | 8.96 | 394.94 | 44.23 | |
| LOSS PER ORDINARY SHARE, DILUTED | 8.96 | 394.94 | 44.23 | |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE | 1 | 41,635 | 111,726 | |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE | 1 | 41,635 | 111,726 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 6 | 1 | 5 | |
| Restricted cash | 27,000 | 35,000 | 25,000 | |
| Prepaid expenses | 570,000 | 966,000 | 335,000 | |
| Other current assets | 49,000 | 62,000 | 24,000 | |
| TOTAL CURRENT ASSETS | 7 | 2 | 5 | |
| Restricted cash | 57,000 | 48,000 | 25,000 | |
| Long-term deposit and other non-current assets | 84,000 | 5,000 | 5,000 | |
| Property and equipment, net | 25,000 | 30,000 | 49,000 | |
| Operating lease right-of-use asset | 412,000 | 530,000 | 198,000 | |
| TOTAL NON-CURRENT ASSETS | 578,000 | 613,000 | 277,000 | |
| TOTAL ASSETS | 7 | 3 | 5 | |
| Trade payables | 787,000 | 929,000 | 319,000 | |
| Current maturities of operating lease liability | 182,000 | 158,000 | 112,000 | |
| Employee related obligations | 879,000 | 642,000 | 207,000 | |
| Other accounts payable | 910,000 | 788,000 | 1 | |
| Private warrants to purchase ordinary shares (including $* and $1 due to related party, as of December 31, 2025 and December 31, 2024, respectively) | — | 2,000 | 0 | |
| Underwriters Promissory Note | 0 | 1 | 0 | |
| TOTAL CURRENT LIABILITIES | 3 | 4 | 2 | |
| Long-term operating lease liability | 286,000 | 368,000 | 59,000 | |
| Related Party Promissory Note | 2 | 3 | 0 | |
| TOTAL NON-CURRENT LIABILITIES | 2 | 3 | 59,000 | |
| TOTAL LIABILITIES | 5 | 7 | 2 | |
| COMMITMENTS AND CONTINGENT LIABILITIES | — | — | — | |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): Ordinary shares ($0.0135 par value per share, 9,000,000 and 1,481,482 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 3,126,651 and 123,290** shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | 42,000 | 2,000 | — | |
| Additional paid-in capital | 58 | 39 | 11 | |
| Accumulated deficit | −55 | −43 | −27 | |
| TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | 3 | −4 | −15 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | 7 | 3 | 5 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −12 | −17 | — | |
| Depreciation | 14,000 | 25,000 | 45,000 | |
| Share-based compensation expenses | 134,000 | 6 | 130,000 | |
| Non-cash loss upon entering Transactions | 0 | 5 | 0 | |
| Other non-cash financial expenses (income) | 344,000 | −1 | 318,000 | |
| Loss (gain) on disposal of property and equipment | 0 | 16,000 | −1,000 | |
| Loss from lease termination | 0 | 68,000 | 0 | |
| Decrease (increase) in prepaid expenses | 396,000 | −631,000 | −329,000 | |
| Decrease (increase) in other current assets | 13,000 | −38,000 | 18,000 | |
| Increase (decrease) in trade payable | −142,000 | 610,000 | 79,000 | |
| Net change in operating lease | −5,000 | −57,000 | 6,000 | |
| Increase in employee related obligations | 237,000 | 435,000 | −46,000 | |
| Increase (decrease) in other accounts payable | 102,000 | −2 | 359,000 | |
| Net cash used in operating activities | −11 | −8 | −5 | |
| Investment in long-term deposits | −5,000 | 0 | — | |
| Purchase of property and equipment | −9,000 | −22,000 | −12,000 | |
| Net cash used in investing activities | −14,000 | −22,000 | 573,000 | |
| Proceeds from issuance of ordinary shares upon January 2025 and September 2025 public offerings | 11 | 0 | — | |
| Issuance costs related to public offerings | −2 | 0 | — | |
| Proceeds from exercise of warrants | 3 | 0 | — | |
| Proceeds from issuance of ordinary shares upon January 2025 and August 2025 warrants inducement transactions | 5 | 0 | — | |
| Issuance costs related to warrants inducement transactions | −740,000 | 0 | — | |
| Payment of underwriters Promissory Note | −696,000 | −250,000 | 0 | |
| Prepaid of issuance cost related to At the Market Offering | −74,000 | 0 | — | |
| Proceeds from exercise of pre-funded options | — | — | 0 | |
| Net proceeds from issuance of ordinary shares (ELOC) | 0 | 3 | 0 | |
| Cash received from Transactions upon the effectiveness of the SPAC Merger | 0 | 2 | 0 | |
| Net cash provided by financing activities | 16 | 5 | 522,000 | |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 5 | −3 | −3 | |
| EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | −2,000 | −61,000 | −230,000 | |
| Derecognition of right-of-use asset recognized and lease liability as a result of operating lease termination | 0 | −89,000 | 0 | |
| Conversion of preferred shares to ordinary shares | 0 | 15 | 0 | |
| Conversion of warrants to preferred shares on a cashless basis | 0 | 334,000 | 0 | |
| Conversion of non-controlling interests to Silexion ordinary shares | 0 | 3 | — | |
| Conversion Of Underwriters Promissory Note To Ordinary Shares | 356,000 | 0 | — | |
| Conversion Of Related Party Promissory Note To Ordinary Shares | 2 | 0 | — | |
| Accrued and unpaid issuance expenses in respect of public offering | 20,000 | 0 | — | |
| Shares issued for ELOC financing liability | 0 | 312,000 | 0 | |
| Right-of-use asset recognized with a corresponding lease liability | 0 | 506,000 | 0 | |
| Interest paid | 13,000 | 27,000 | 0 | |
| Interest received | 155,000 | 28,000 | 153,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Silexion Therapeutics Corp's CIK number?
Silexion Therapeutics Corp's SEC CIK number is 0002022416 (2022416). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Silexion Therapeutics Corp's SEC filings?
All of Silexion Therapeutics Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Silexion Therapeutics Corp last report earnings?
Silexion Therapeutics Corp (SLXN) most recently filed an earnings 8-K with the SEC on May 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001178913-26-002761). This is Silexion Therapeutics Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is Silexion Therapeutics Corp's most recent earnings 8-K?
Silexion Therapeutics Corp's latest earnings 8-K (Item 2.02) was filed May 18, 2026 under accession 0001178913-26-002761. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Silexion Therapeutics Corp's latest earnings 8-K →
Look up any company's CIK number →